Acrivon Therapeutics, Inc. Common Stock (ACRV) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Acrivon Therapeutics, Inc. Common Stock (ACRV) Earnings Overview
As of June 28, 2026, Acrivon Therapeutics, Inc. Common Stock (ACRV) reported trailing twelve-month net income of -$77M, reflecting +3.8% year-over-year growth. The company earned $-2.00 per diluted share over the past four quarters.
Looking at the long-term picture, ACRV's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2020.
Acrivon Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AUPH ($298M net income, 101.5% margin), KYMR (-$315M net income, -794.4% margin), TNGX (-$107M net income, -162.9% margin), ACRV has comparable earnings metrics. Compare ACRV vs AUPH →
ACRV Earnings vs Peers
Earnings metrics vs comparable public companies
ACRV Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$78M | +3.3% | -$84M | $-2.02 | - | - |
| 2024 | -$81M | -33.4% | -$89M | $-2.10 | - | - |
| 2023 | -$60M | -93.8% | -$67M | $-2.74 | - | - |
| 2022 | -$31M | -91.9% | -$33M | $-1.42 | - | - |
| 2021 | -$16M | -206.1% | -$16M | $-1.26 | - | - |
| 2020 | -$5M | - | -$3M | $-0.41 | - | - |
Download Data
Export ACRV earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ACRV — Frequently Asked Questions
Quick answers to the most common questions about buying ACRV stock.
What is ACRV earnings per share (EPS)?
ACRV trailing twelve-month (TTM) diluted EPS is $-2.00, reflecting +3.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Acrivon Therapeutics, Inc. Common Stock's net income?
Acrivon Therapeutics, Inc. Common Stock (ACRV) trailing twelve-month net income is $-77M as of 2025. Earnings grew +3.8% year-over-year.
Is ACRV profitable?
ACRV is not currently profitable on a TTM basis, reporting a net loss of $-77M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ACRV's earnings growth rate?
ACRV compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are ACRV's profit margins?
Acrivon Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -53.9%.
Is ACRV growing earnings?
ACRV earnings growth is slowing. Current YoY EPS growth of +3.8% trails the 5-year CAGR of N/A. TTM net income is $-77M.
What was ACRV's best earnings year?
Acrivon Therapeutics, Inc. Common Stock's highest annual net income on record is $-5M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were ACRV's earnings last quarter?
ACRV's most recent reported quarter was Q1 2026. Net income was $-19M with diluted EPS of $-0.49. For a full breakdown of all quarters, see the quarterly earnings table on this page.